{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T17:40:16Z","timestamp":1725817216929},"reference-count":46,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["mdconsult.com","theclinics.com","labmed.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Laboratory Medicine"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.cll.2014.06.001","type":"journal-article","created":{"date-parts":[[2014,7,18]],"date-time":"2014-07-18T12:16:38Z","timestamp":1405685798000},"page":"623-635","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Prothrombin Complex Concentrates as Reversal Agents for New Oral Anticoagulants"],"prefix":"10.1016","volume":"34","author":[{"given":"Gerhard","family":"Dickneite","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.cll.2014.06.001_bib1","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.3949\/ccjm.72.Suppl_1.S2","article-title":"A\u00a0pharmacologic overview of current and emerging anticoagulants","volume":"72","author":"Nutescu","year":"2005","journal-title":"Cleve Clin J Med"},{"issue":"73","key":"10.1016\/j.cll.2014.06.001_bib2","first-page":"445","article-title":"Development and clinical applications of novel oral anticoagulants. Part II. Drugs under clinical investigation","volume":"13","author":"Ahrens","year":"2012","journal-title":"Discov Med"},{"issue":"1","key":"10.1016\/j.cll.2014.06.001_bib3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.5482\/ha-1186","article-title":"Anticoagulation in atrial fibrillation: a new era has begun","volume":"32","author":"Moser","year":"2012","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.cll.2014.06.001_bib4","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1146\/annurev-med-062209-095159","article-title":"Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism","volume":"62","author":"Eriksson","year":"2011","journal-title":"Annu Rev Med"},{"issue":"73","key":"10.1016\/j.cll.2014.06.001_bib5","first-page":"433","article-title":"Development and clinical applications of novel oral anticoagulants. Part I. Clinically approved drugs","volume":"13","author":"Ahrens","year":"2012","journal-title":"Discov Med"},{"issue":"6","key":"10.1016\/j.cll.2014.06.001_bib6","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.thromres.2010.09.008","article-title":"The mechanism of action of rivaroxaban\u2014an oral, direct factor Xa inhibitor\u2013compared with other anticoagulants","volume":"127","author":"Samama","year":"2011","journal-title":"Thromb Res"},{"issue":"21","key":"10.1016\/j.cll.2014.06.001_bib7","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1056\/NEJMsa1103053","article-title":"Emergency hospitalizations for adverse drug events in older Americans","volume":"365","author":"Budnitz","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.cll.2014.06.001_bib8","doi-asserted-by":"crossref","first-page":"755","DOI":"10.7326\/0003-4819-147-11-200712040-00006","article-title":"Medication use leading to emergency department visits for adverse drug events in older adults","volume":"147","author":"Budnitz","year":"2007","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.cll.2014.06.001_bib9","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1161\/STROKEAHA.111.615260","article-title":"Effect of increased warfarin use on warfarin-related cerebral hemorrhage: a longitudinal population-based study","volume":"42","author":"Huhtakangas","year":"2011","journal-title":"Stroke"},{"issue":"8","key":"10.1016\/j.cll.2014.06.001_bib10","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/archinte.164.8.880","article-title":"The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage","volume":"164","author":"Rosand","year":"2004","journal-title":"Arch Intern Med"},{"issue":"13","key":"10.1016\/j.cll.2014.06.001_bib11","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/archinte.167.13.1414","article-title":"Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action","volume":"167","author":"Wysowski","year":"2007","journal-title":"Arch Intern Med"},{"issue":"2 Suppl","key":"10.1016\/j.cll.2014.06.001_bib12","doi-asserted-by":"crossref","first-page":"e152S","DOI":"10.1378\/chest.11-2295","article-title":"Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Holbrook","year":"2012","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.cll.2014.06.001_bib13","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1111\/j.1742-1241.2008.01859.x","article-title":"Biochemical comparison of seven commercially available prothrombin complex concentrates","volume":"62","author":"Kalina","year":"2008","journal-title":"Int J Clin Pract"},{"issue":"11","key":"10.1016\/j.cll.2014.06.001_bib14","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1161\/CIRCULATIONAHA.113.002283","article-title":"Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study","volume":"128","author":"Sarode","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.cll.2014.06.001_bib15","unstructured":"Sarode R. Four-factor prothrombin complex concentrate versus plasma for urgent VKA reversal: what's new? Clin Lab Med, in press."},{"issue":"14","key":"10.1016\/j.cll.2014.06.001_bib16","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/CIRCULATIONAHA.111.029017","article-title":"Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects","volume":"124","author":"Eerenberg","year":"2011","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.cll.2014.06.001_bib17","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.3324\/haematol.2013.092767","article-title":"Use of prothrombin complex concentrates for urgent reversal of dabigatran in the emergency department","volume":"98","author":"Diaz","year":"2013","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.cll.2014.06.001_bib18","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1538-7836.2008.02904.x","article-title":"Prothrombin complex concentrate (Beriplex P\/N) for emergency anticoagulation reversal: a prospective multinational clinical trial","volume":"6","author":"Pabinger","year":"2008","journal-title":"J\u00a0Thromb Haemost"},{"issue":"2","key":"10.1016\/j.cll.2014.06.001_bib19","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1160\/TH13-05-0431","article-title":"Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?","volume":"111","author":"Dickneite","year":"2013","journal-title":"Thromb Haemost"},{"issue":"9","key":"10.1016\/j.cll.2014.06.001_bib20","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1111\/j.1538-7836.2012.04859.x","article-title":"Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P\/N) in a rabbit model","volume":"10","author":"Pragst","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.cll.2014.06.001_bib21","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood.V120.21.3420.3420","article-title":"Partial reversal of dabigatran effect by a prothrombin complex concentrate in a model of thrombin generation (2012 ASH abstracts)","volume":"120","author":"Hoffman","year":"2012","journal-title":"Blood"},{"issue":"Suppl s2","key":"10.1016\/j.cll.2014.06.001_bib22","first-page":"562","article-title":"Antidotal effects of non-specific reversal agents on anticoagulant-induced inhibition of thrombin generation (2013 ISTH abstracts)","volume":"11","author":"Pillitteri","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"issue":"21","key":"10.1016\/j.cll.2014.06.001_bib23","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1182\/blood.V120.21.2261.2261","article-title":"Reversal of the antithrombotic action of rivaroxaban and dabigatran: a clinical study in healthy volunteers. (2012 ASH abstracts)","volume":"120","author":"Galan","year":"2012","journal-title":"Blood"},{"issue":"Suppl s2","key":"10.1016\/j.cll.2014.06.001_bib24","first-page":"418","article-title":"Effects of rivaroxaban and dabigatran on hemostasis and reversion of their antithrombotic effects by different coagulation factors. Evidence raised from a clinical study in healthy volunteers (2013 ISTH abstracts)","volume":"11","author":"Galan","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"issue":"12","key":"10.1016\/j.cll.2014.06.001_bib25","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1161\/STROKEAHA.111.624650","article-title":"Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran","volume":"42","author":"Zhou","year":"2011","journal-title":"Stroke"},{"key":"10.1016\/j.cll.2014.06.001_bib26","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood.V118.21.2316.2316","article-title":"The successful reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat tail bleeding model do not correlate with ex\u00a0vivo markers of anticoagulation (2011 ASH abstracts)","volume":"118","author":"van Ryn","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.cll.2014.06.001_bib27","unstructured":"Herzog E, Kaspereit F, Krege W, et\u00a0al. Pre-clinical safety aspects on the use of Beriplex P\/N for reversal of Dabigatran anticoagulation [abstract P5-1]. Paper presented at: 57th Annual Meeting of the German Thrombosis and Haemostasis Research Society. Munich, Germany, February 20\u201323, 2013."},{"issue":"Suppl s2","key":"10.1016\/j.cll.2014.06.001_bib28","first-page":"693","article-title":"Non-clinical safety and efficacy of prothrombin complex concentrates (PCC) for the reversal of dabigatran mediated anticoagulation (2013 ISTH abstracts)","volume":"11","author":"Herzog","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.cll.2014.06.001_bib29","unstructured":"van Ryn J, Schurer J, Kink-Eiband M, et\u00a0al. Successful reversal of dabigatran-induced bleeding by 3-factor coagulation concentrates in a rat tail bleeding model: lack of correlation with ex\u00a0vivo markers of anticoagulation. Paper presented at: AHA Scientific Sessions and Resuscitation Science Symposium. Los Angeles, USA, November 3\u20135, 2012."},{"issue":"Suppl s2","key":"10.1016\/j.cll.2014.06.001_bib30","first-page":"953","article-title":"Alterations induced by rivaroxaban on hemostasis can be reversed by different coagulation factor concentrates: in\u00a0vitro experimental studies with steady and circulating human blood (2013 ISTH abstracts)","volume":"11","author":"Arellano-Rodrigo","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"issue":"3","key":"10.1016\/j.cll.2014.06.001_bib31","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1161\/STROKEAHA.112.675231","article-title":"Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban","volume":"44","author":"Zhou","year":"2013","journal-title":"Stroke"},{"issue":"1","key":"10.1016\/j.cll.2014.06.001_bib32","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1160\/TH12-12-0907","article-title":"Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates","volume":"110","author":"Perzborn","year":"2013","journal-title":"Thromb Haemost"},{"issue":"Suppl s2","key":"10.1016\/j.cll.2014.06.001_bib33","first-page":"167","article-title":"Effects of three-factor and four-factor prothrombin complex concentrates on the pharmacodynamics of rivaroxaban (2013 ISTH abstracts)","volume":"11","author":"Levi","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"issue":"11","key":"10.1016\/j.cll.2014.06.001_bib34","doi-asserted-by":"crossref","first-page":"e78696","DOI":"10.1371\/journal.pone.0078696","article-title":"Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in\u00a0vitro with circulating human blood","volume":"8","author":"Escolar","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cll.2014.06.001_bib35","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1182\/blood.V122.21.1133.1133","article-title":"Four-factor prothrombin complex concentrate (4-PCC) effectively reverses edoxaban induced bleeding in a rabbit model of acute injury (2013 ASH abstracts)","volume":"122","author":"Herzog","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cll.2014.06.001_bib36","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/cc9311","article-title":"Clinical review: prothrombin complex concentrates\u2014evaluation of safety and thrombogenicity","volume":"15","author":"Sorensen","year":"2011","journal-title":"Crit Care"},{"issue":"4","key":"10.1016\/j.cll.2014.06.001_bib37","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/jth.12149","article-title":"Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis","volume":"11","author":"Baglin","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"issue":"4","key":"10.1016\/j.cll.2014.06.001_bib38","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/j.thromres.2011.07.026","article-title":"In\u00a0vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux","volume":"129","author":"Samama","year":"2012","journal-title":"Thromb Res"},{"issue":"9","key":"10.1016\/j.cll.2014.06.001_bib39","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1111\/j.1538-7836.2012.04863.x","article-title":"Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate","volume":"10","author":"Lambourne","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"issue":"6","key":"10.1016\/j.cll.2014.06.001_bib40","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/j.1537-2995.2008.02080.x","article-title":"Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose","volume":"49","author":"Holland","year":"2009","journal-title":"Transfusion"},{"issue":"1","key":"10.1016\/j.cll.2014.06.001_bib41","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/ALN.0b013e318238c036","article-title":"Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model","volume":"116","author":"Godier","year":"2012","journal-title":"Anesthesiology"},{"issue":"5","key":"10.1016\/j.cll.2014.06.001_bib42","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1160\/TH12-03-0209","article-title":"Management consensus guidance for the use of rivaroxaban\u2014an oral, direct factor Xa inhibitor","volume":"108","author":"Turpie","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.cll.2014.06.001_bib43","doi-asserted-by":"crossref","first-page":"12","DOI":"10.15420\/aer.2012.1.12","article-title":"Anticoagulation in atrial fibrillation","volume":"1","author":"Ahmad","year":"2012","journal-title":"Arrhythmia & Electrophysiology Review"},{"issue":"4","key":"10.1016\/j.cll.2014.06.001_bib44","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nm.3102","article-title":"A\u00a0specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa","volume":"19","author":"Lu","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.cll.2014.06.001_bib45","doi-asserted-by":"crossref","unstructured":"van Ryn J, Litzenburger T, Waterman A, et\u00a0al. An antibody selective to dabigatran safely neutralizes both dabigatran-induced anticoagulant and bleeding activity in in\u00a0vitro and in\u00a0vivo models [Abstract P-MO-166]. Paper presented at: 57th Annual Meeting of the International Society on Thrombosis and Haemostasis. Kyoto, Japan, July 23\u201328, 2011.","DOI":"10.1016\/S0735-1097(11)61130-3"},{"key":"10.1016\/j.cll.2014.06.001_bib46","doi-asserted-by":"crossref","unstructured":"van Ryn J, Litzenburger T, Schurer J. Reversal of anticoagulant activity of dabigatran and dabigatran-induced bleeding in rats by a specific antidote (antibody fragment) [abstract 9928]. Paper presented at: American Heart Association Scientific Sessions and Resuscitation Science Symposium. Los Angeles, USA, November 3\u20137, 2012.","DOI":"10.1161\/circ.126.suppl_21.A9928"}],"container-title":["Clinics in Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271214000456?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271214000456?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T21:15:39Z","timestamp":1717103739000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272271214000456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0272271214000456"],"URL":"https:\/\/doi.org\/10.1016\/j.cll.2014.06.001","relation":{},"ISSN":["0272-2712"],"issn-type":[{"value":"0272-2712","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prothrombin Complex Concentrates as Reversal Agents for New Oral Anticoagulants","name":"articletitle","label":"Article Title"},{"value":"Clinics in Laboratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cll.2014.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}